Peter MD Review: Pricing, Treatment Quality, and Real Results

Peter MD requires full blood work before initiating treatment, and this represents a genuine clinical standard. The required panel typically includes: Total testosterone: The primary diagnostic measure. Normal range is approximately 300-1000 ng/dL; clinical hypogonadism is typically defined as under 300 ng/dL on two separate morning measurements. Peter MD uses these standard diagnostic thresholds. Free testosterone: Important because total testosterone includes protein-bound testosterone that is not biologically active. Men with normal total T but high SHBG (sex hormone-binding globulin) may have low free testosterone and experience symptoms of hypogonadism. LH and FSH: These pituitary hormones indicate whether low testosterone is primary (testicular failure, where LH/FSH are high) or secondary (hypothalamic/pituitary issue, where LH/FSH are low or inappropriately normal). This distinction matters for how TRT is structured and whether fertility preservation is a concern. Hematocrit: TRT raises red blood cell count (polycythemia is a known side effect). Baseline hematocrit above 54% is a contraindication to TRT, and monitoring during treatment is required. PSA: Prostate-specific antigen is monitored because TRT may accelerate prostate tissue growth in men with subclinical prostate cancer. Elevated PSA warrants further evaluation before starting TRT. complete metabolic panel and CBC: Liver function, kidney function, and complete blood count provide baseline safety markers. This is the same panel a board-certified endocrinologist or urologist would order before initiating TRT. Many telehealth platforms skip these labs or make them optional. Peter MD makes them mandatory, which sets a higher standard of care.

Peter MD offers multiple TRT delivery formats, which matters clinically because different methods produce different testosterone release profiles and have different practical implications for patients:

Injectable testosterone cypionate: The most common TRT formulation in the US. Self-administered subcutaneous or intramuscular injection, typically weekly. Produces peak testosterone levels 1-2 days post-injection with a gradual decline over 7 days. Some patients experience mood fluctuations corresponding to this peak-trough cycle. Inexpensive.

Testosterone cypionate pellets: Not typically offered through Peter MD; pellet therapy requires a minor in-office procedure.

Topical testosterone gel or cream: Applied to the skin daily (usually shoulders, upper arms, or abdomen). More stable testosterone levels than injections with less peak-trough variation. Risk of transfer to partners or children through skin contact. Requires consistent daily application.

Testosterone nasal gel: Natesto - delivered intranasally three times daily. Maintains testicular testosterone production better than other forms, which matters for fertility preservation. Shorter duration means less impact on the HPG axis feedback suppression.

Peter MD providers match the formulation to the patient's situation: fertility goals, lifestyle, injection tolerance, and testosterone dynamics under each delivery method. Most patients on TRT through telehealth platforms receive testosterone cypionate injections as the default, and Peter MD generally follows this pattern while offering alternatives when indicated.

Testosterone replacement therapy requires ongoing monitoring. Follow-up labs at 6-8 weeks evaluate total testosterone, hematocrit, and PSA to confirm therapeutic response and screen for early safety signals. Hematocrit above 54% requires dose adjustment. PSA elevation requires prostate evaluation before continuing.

Erectile dysfunction and low testosterone frequently coexist. Testosterone is not the primary driver of erections - vascular function and nitric oxide signaling are - but testosterone maintains libido, sexual motivation, and contributes to the hormonal environment in which erections occur. Studies show that men with confirmed hypogonadism have meaningfully higher rates of ED than age-matched controls with normal testosterone.

Peter MD prescribes standard ED medications - sildenafil and tadalafil - alongside TRT when appropriate. For men with ED driven primarily by low testosterone (typically presenting as reduced libido, morning erection loss, and generalized energy issues alongside ED), TRT often improves erectile function without or alongside PDE5 inhibitors. Prescribing ED medication without checking testosterone levels first is treating a symptom without evaluating the cause.

For men with ED secondary to TRT treatment itself - paradoxically, some men experience temporary ED when starting TRT as the HPG axis adjusts - Peter MD providers can manage this transition with appropriate medication support.

The combination of ED medication and TRT at Peter MD is handled within a single clinical relationship rather than requiring two separate platforms, which reduces clinical fragmentation and allows the provider to make coordinated decisions about both treatment components.

Peter MD has expanded into GLP-1 weight loss treatment, following the broader telehealth trend. Compounded semaglutide and tirzepatide are available through the platform. The clinical advantage Peter MD brings to weight loss is its lab infrastructure: before starting GLP-1 treatment, the same complete metabolic baseline that applies to TRT can provide relevant context - insulin resistance, metabolic health markers, thyroid function - that informs the weight loss clinical picture.

For men who want both TRT and GLP-1 weight loss treatment, Peter MD handles both in a single clinical relationship. This matters because TRT and semaglutide interact metabolically: TRT can improve body composition (increased lean mass, decreased fat mass) that complements GLP-1-driven weight loss. Managing both under unified clinical oversight reduces the risk of clinicians making decisions about one treatment without knowing about the other.

Pricing for GLP-1 treatment at Peter MD is competitive with the broader market - $199-279/month for compounded semaglutide depending on dose. Monthly check-ins are included.

For weight loss as a standalone goal without TRT, platforms with more developed behavioral support (Ro Body, Henry Meds) may offer richer programming. Peter MD is best as an integrated platform for men managing both hormone health and weight simultaneously.

Peter MD uses subscription pricing with the lab infrastructure built into the program:

Initial evaluation including complete labs: $99-149 (one-time, includes the baseline lab panel and provider consultation to review results and develop a treatment plan)

Monthly TRT subscription: $99-149/month depending on formulation. Includes medication, ongoing provider access, and quarterly check-in coordination.

ED medication: $40-80/month for sildenafil or tadalafil, depending on dose and quantity.

GLP-1 (compounded semaglutide): $199-279/month depending on dose.

The lab cost is included in the evaluation fee rather than billed separately - an important practical detail, because labs at conventional pricing run $100-300. The evaluation fee covers both the lab costs and the provider consultation to review results.

Follow-up labs during treatment (required every 3-6 months) may be billed separately or included depending on the specific subscription tier. The Peter MD website details current pricing structures which have evolved as the platform has grown.

For men who are new to TRT and want to start properly with a full diagnostic workup and evidence-based treatment, the initial evaluation cost is well worth it - it is the same workup an endocrinologist would perform, at a fraction of the cost and without the months-long wait.

Peter MD is designed for a specific patient profile: men in their 30s, 40s, and 50s who are experiencing symptoms potentially related to low testosterone - reduced libido, fatigue, decreased morning erections, mood changes, difficulty maintaining muscle mass, reduced exercise recovery - and want a diagnostically rigorous approach to evaluating and treating those symptoms.

The lab-first model means Peter MD serves men who want to know their actual numbers before making treatment decisions. If your testosterone is 400 ng/dL (within normal range) but you have symptoms, the clinical conversation about whether TRT is appropriate is different from a man with testosterone at 180 ng/dL. Peter MD enables that informed conversation.

Men who have been told by a primary care physician that their testosterone is "normal" but feel it should be evaluated more carefully are a natural fit. Primary care physicians often use labs that measure total testosterone without free testosterone or SHBG, which can miss men with low bioavailable testosterone despite normal-appearing totals.

Peter MD is less compelling for men who want ED treatment unrelated to hormonal issues - for straightforward vascular ED, a simpler platform with sildenafil prescriptions at $15-25/month is more cost-effective. And for complex hormone disorders requiring subspecialty endocrinology, in-person specialist care is more appropriate than telehealth TRT management.

The most clinically significant TRT risks requiring monitoring are cardiovascular (elevated hematocrit increases thrombotic risk), prostate (testosterone can accelerate pre-existing prostate cancer), and fertility (exogenous testosterone suppresses spermatogenesis). Peter MD monitors all three through scheduled lab intervals.

Polycythemia (elevated red blood cell count and hematocrit): TRT stimulates erythropoiesis. If hematocrit exceeds 54%, blood viscosity increases and clotting risk rises. This is the most common reason TRT doses need to be reduced or temporarily interrupted. Regular hematocrit monitoring - which Peter MD requires - catches this before it becomes a problem.

Prostate effects: TRT does not cause prostate cancer, but it can accelerate growth of pre-existing prostate cancer. PSA monitoring before and during TRT is the standard of care. A significant PSA rise during TRT prompts evaluation.

Cardiovascular effects: The relationship between TRT and cardiovascular outcomes has been studied extensively with conflicting findings. Current evidence suggests TRT at physiological replacement doses is not associated with increased cardiovascular risk in most men, but men with existing cardiovascular disease warrant careful evaluation. Peter MD screens for cardiovascular history in the initial evaluation.

Infertility: TRT suppresses FSH and LH, which reduces or eliminates sperm production. This is reversible upon discontinuation for most men, but recovery can take months. Men who want to preserve fertility should discuss options - including human chorionic gonadotropin (hCG) supplementation alongside TRT or switching to nasal testosterone - with their Peter MD provider before starting treatment.

Testicular atrophy: A predictable consequence of exogenous testosterone suppressing natural production. Cosmetically notable for some men; hCG supplementation can maintain testicular volume.

The telehealth TRT market includes platforms ranging from very low rigor (symptom questionnaire to prescription) to complete clinical programs. Peter MD positions in the higher-rigor segment without requiring in-person visits.

Compared to Maximus (a competitor in the TRT space), Peter MD offers a similar lab-first approach. Both require blood work before prescribing. The differentiators come in monitoring protocol intensity, provider accessibility, and pricing.

Compared to in-person TRT clinics (which typically charge $150-300/month plus clinic visit fees), Peter MD offers comparable clinical rigor at lower cost by eliminating the in-person overhead.

Compared to platforms that prescribe TRT after a symptom questionnaire without requiring labs, Peter MD provides a more defensible clinical standard that protects both the patient (ensuring treatment is actually indicated) and the provider (documenting the clinical rationale for prescribing).

The lab requirement does add 1-2 weeks to the time-to-treatment compared to platforms that skip that step. For men who want to start treatment immediately, this may feel like a delay. For men who want to know their actual hormone levels and have a data-based clinical rationale for treatment, the delay is the feature, not a bug.